The Market is segmented by Management Devices (Insulin Pumps, Insulin Syringes, Insulin Disposable Pens, Insulin Cartridges in Reusable Pens, Insulin Jet Injectors) and Monitoring Devices (Self-monitoring Blood Glucose and Continuous Glucose Monitoring), and Geography.

Market Snapshot

Canada Diabetes Care Devices Market Overview
Study Period: 2016-2027
Base Year: 2021
CAGR: >6 %

Need a report that reflects how COVID-19 has impacted this market and its growth?

Market Overview

The Canada Diabetes Care Devices Market is expected to reach more than USD 2.1 billion by 2026, at a CAGR of 6.3% during the forecast period (2021 - 2026). Monitoring devices are anticipated to dominate the market during the forecast period, owing to the rising prevalence of diabetes and an increase in the number of device users in the country. There has been a significant rise in insulin delivery systems technology, from insulin injections to insulin pumps. Technological innovations and advances give many conveniences in measuring blood glucose levels. One such advancement in monitoring blood glucose levels has been established with continuous glucose monitoring devices. Therefore, the number of diabetic patients is expected to increase in the future. There is also a concern that diabetes might affect the youth, due to the sedentary lifestyle. This factor is expected to boost the adoption of continuous glucose monitoring devices. This factor, in turn, is expected to drive the growth of the market.

Scope of the Report

In the Canada diabetes care devices market, the market studied is segmented into management and monitoring devices. The monitoring devices segment is further sub-segmented into blood glucose monitoring and continuous glucose monitoring. Similarly, the management devices segment is further sub-segmented into Insulin Pumps, Insulin Syringes, Insulin Disposable Pens, Insulin Cartridges in Reusable Pens, Insulin Jet Injectors. A holistic study of the market studied has been carried out by incorporating various factors, extending from country-specific demographic conditions and business cycles to market-specific microeconomic influences, which are required to analyze the future trends.

By Device
By Monitoring Devices, (Value and Volume, 2016 - 2026)
Self-monitoring Blood Glucose Devices
Glucometer Devices
Test Strips
Continuous Glucose Monitoring
Receivers (Receivers and Transmitters)
By Management Devices, (Value and Volume, 2016 - 2026)
Insulin Delivery Devices
Insulin Pump
Insulin Pump Device
Insulin Pump Reservoir
Infusion Set
Insulin Syringes
Insulin Disposable Pens
Insulin Cartridges in Reusable pens
Insulin Jet Injectors
By Drug
Oral Anti-diabetic drugs (Value and Volume 2016 - 2026)
Alpha-glucosidase Inhibitors
Dopamine -D2 Receptor Agonist
Cycloset (Bromocriptin)
Sodium-glucose Cotransport -2 (SGLT-2) Inhibitors
Invokana (Canagliflozin)
Jardiance (Empagliflozin)
Farxiga/Forxiga (Dapagliflozin)
Suglat (Ipragliflozin)
Dipeptidyl Peptidase-4 (DPP-4) Inhibitors
Januvia (Sitagliptin)
Onglyza (Saxagliptin)
Tradjenta (Linagliptin)
Vipidia/Nesina (Alogliptin)
Galvus (Vildagliptin)
Insulin (Value and Volume 2016 - 2026)
Basal or Long-acting Insulin
Lantus (Insulin Glargine)
Levemir (Insulin Detemir)
Toujeo (Insulin Glargine)
Tresiba (Insulin Degludec)
Basaglar (Insulin Glargine)
Bolus or Fast-acting Insulin
NovoRapid/Novolog (Insulin Aspart)
Humalog (Insulin Lispro)
Apidra (Insulin Glulisine)
Traditional Human Insulin
Biosimilar Insulin
Insulin Glargine Biosimilars
Human Insulin Biosimilars
Non-insulin Injectable Drug (Value and Volume 2016 - 2026)
GLP-1 Receptor Agonists
Victoza (Liraglutide)
Byetta (Exenatide)
Bydureon (Exenatide)
Trulicity (Dulaglutide)
Lyxumia (Lixisenatide)
Amylin Analogue
Symlin (Pramlintide)
Combination Drug
Combination Insulin
NovoMix (Biphasic Insulin Aspart)
Ryzodeg (Insulin Degludec and Insulin Aspart)
Xultophy (Insulin Degludec and Liraglutide)
Oral Combination
Janumet (Sitagliptin and Metformin HCl)

Report scope can be customized per your requirements. Click here.

Key Market Trends

Test strips occupy the highest market share among the Monitoring devices for the year 2020

In Canada, the type-1 diabetes population is expected to witness a CAGR of 1.5%, by 2026. The users of glucometers will increase as type-1 diabetes patients will increase. It is estimated that in 2026 there will be 340 thousand people suffering from type-1 diabetes. Home use of test strip is also increasing because of initiatives of provincial governments across Canada. They have implemented the blood glucose test strip (BGTS) quantity limits to encourage proper testing practices for optimal patient outcomes. In Alberta, insulin-dependent patients are eligible for coverage of a USD 600 in a year, other regions also have reimbursement policies. Therefore, if a patient performs 5-6 tests in a day, the average expenditure on test strips would be more than USD 100/month. These expenses add to the already high diabetes management costs and are impeding the market growth. the growth in market volume and share of strips is expected to be higher than that of glucose meters, because of the difference in use-case frequency. Furthermore, the average life-span of glucose meter ranges between 6 months to 3 years.

Diabetes Population

Insulin Pumps Occupy the Highest Share in the Management Devices Segment

The use of Insulin pumps is rising among developed countries. These are the devices that mimic the human pancreas, i.e., there would be continuous subcutaneous insulin administration in small amounts. Insulin pumps deliver rapid- or short-acting insulin 24 hours a day through a catheter placed under the skin. The insulin pump usage among Canadian patients increased due to the accurate dosage of administration and patients who are not able to meet the insulin requirements accurately. Thus, the CAGR growth is expected to be more than 4.83% during the forecast period for insulin pumps in the Canada diabetes care devices market. The technological advancements in the infusion set of the insulin pump, like concealing the needle of the infusion set and the pre-loaded, disposable, and single-use inserter that enables the patients to change infusion sets without carrying a separate inserter, are likely to drive the market. Diabetes Canada and the Canadian Pharmacists Association (CPhA) are actively monitoring coronavirus issues, in collaboration with the Canadian local government and diabetes devices manufacturers, to remain available for all Canadians, and stated that “based on the information from device manufacturers, there have been no COVID-19 related shortages reported in Canada”.

Revenue share

Competitive Landscape

There have been constant innovations driven by manufacturers to compete in the market. The major players, such as Abbott and Medtronic, have undergone many mergers, acquisitions, and partnerships, to establish market dominance, while also adhering to organic growth strategies, which is evident from the R&D spending of these companies. 


In Dec 2020, Abbott’s continuous glucose monitoring system, the FreeStyle Libre 2, has been approved in Canada for adults and children four years and older with diabetes.

In Nov 2020, Tandem Diabetes Care Announces Health Canada Approval of the t: slim X2 Insulin Pump with Control-IQ Advanced Hybrid Closed-Loop Technology.

Table of Contents


    1. 1.1 Study Assumptions

    2. 1.2 Scope of the Study




    1. 4.1 Market Overview

    2. 4.2 Market Dynamics

      1. 4.2.1 Market Drivers

      2. 4.2.2 Market Restraints

    3. 4.3 Industry Attractiveness - Porter's Five Forces Analysis

      1. 4.3.1 Bargaining Power of Suppliers

      2. 4.3.2 Bargaining Power of Consumers

      3. 4.3.3 Threat of New Entrants

      4. 4.3.4 Threat of Substitute Products and Services

      5. 4.3.5 Intensity of Competitive Rivalry

  5. 5. Market Segmentation

    1. 5.1 By Device

      1. 5.1.1 By Monitoring Devices, (Value and Volume, 2016 - 2026)

        1. Self-monitoring Blood Glucose Devices

          1. Glucometer Devices

          2. Test Strips

          3. Lancets

        2. Continuous Glucose Monitoring

          1. Sensors

          2. Receivers (Receivers and Transmitters)

      2. 5.1.2 By Management Devices, (Value and Volume, 2016 - 2026)

        1. Insulin Delivery Devices

          1. Insulin Pump

            1. Insulin Pump Device

            2. Insulin Pump Reservoir

            3. Infusion Set

          2. Insulin Syringes

          3. Insulin Disposable Pens

          4. Insulin Cartridges in Reusable pens

          5. Insulin Jet Injectors

    2. 5.2 By Drug

      1. 5.2.1 Oral Anti-diabetic drugs (Value and Volume 2016 - 2026)

        1. Biguanides

          1. Metformin

        2. Alpha-glucosidase Inhibitors

        3. Dopamine -D2 Receptor Agonist

          1. Cycloset (Bromocriptin)

        4. Sodium-glucose Cotransport -2 (SGLT-2) Inhibitors

          1. Invokana (Canagliflozin)

          2. Jardiance (Empagliflozin)

          3. Farxiga/Forxiga (Dapagliflozin)

          4. Suglat (Ipragliflozin)

        5. Dipeptidyl Peptidase-4 (DPP-4) Inhibitors

          1. Januvia (Sitagliptin)

          2. Onglyza (Saxagliptin)

          3. Tradjenta (Linagliptin)

          4. Vipidia/Nesina (Alogliptin)

          5. Galvus (Vildagliptin)

        6. Sulfonylureas

        7. Meglitinides

      2. 5.2.2 Insulin (Value and Volume 2016 - 2026)

        1. Basal or Long-acting Insulin

          1. Lantus (Insulin Glargine)

          2. Levemir (Insulin Detemir)

          3. Toujeo (Insulin Glargine)

          4. Tresiba (Insulin Degludec)

          5. Basaglar (Insulin Glargine)

        2. Bolus or Fast-acting Insulin

          1. NovoRapid/Novolog (Insulin Aspart)

          2. Humalog (Insulin Lispro)

          3. Apidra (Insulin Glulisine)

        3. Traditional Human Insulin

          1. Novolin/Actrapid/Insulatard

          2. Humulin

          3. Insuman

        4. Biosimilar Insulin

          1. Insulin Glargine Biosimilars

          2. Human Insulin Biosimilars

      3. 5.2.3 Non-insulin Injectable Drug (Value and Volume 2016 - 2026)

        1. GLP-1 Receptor Agonists

          1. Victoza (Liraglutide)

          2. Byetta (Exenatide)

          3. Bydureon (Exenatide)

          4. Trulicity (Dulaglutide)

          5. Lyxumia (Lixisenatide)

        2. Amylin Analogue

          1. Symlin (Pramlintide)

      4. 5.2.4 Combination Drug

        1. Combination Insulin

          1. NovoMix (Biphasic Insulin Aspart)

          2. Ryzodeg (Insulin Degludec and Insulin Aspart)

          3. Xultophy (Insulin Degludec and Liraglutide)

        2. Oral Combination

          1. Janumet (Sitagliptin and Metformin HCl)


    1. 6.1 Type 1 Diabetes Population (2016 - 2026)

    2. 6.2 Type 2 Diabetes Population (2016 - 2026)



      1. 7.1.1 Novo Nordisk A/S

      2. 7.1.2 Sanofi Aventis

      3. 7.1.3 Eli Lilly

      4. 7.1.4 F. Hoffmann-La Roche Ltd

      5. 7.1.5 Abbott Diabetes Care

      6. 7.1.6 Johnson and Johnson (Lifescan)

      7. 7.1.7 Arkray

      8. 7.1.8 Ascensia Diabetes Care

      9. 7.1.9 AgaMatrix Inc.

      10. 7.1.10 Dexcom

      11. 7.1.11 Medtronic

      12. 7.1.12 Ypsomed Holding AG

      13. 7.1.13 Terumo

      14. 7.1.14 LMC Diabetes and Endocrinology

      15. 7.1.15 Bayshore Health Care

      16. 7.1.16 Express Scripts

      17. 7.1.17 One Drop

      18. 7.1.18 TELUS Health


You can also purchase parts of this report. Do you want to check out a section wise price list?

Frequently Asked Questions

The Canada Diabetes Care Devices Market market is studied from 2016 - 2026.

The Canada Diabetes Care Devices Market is growing at a CAGR of >6% over the next 5 years.

The Canada Diabetes Care Devices Market is valued at 1 Billion USD in 2016.

The Canada Diabetes Care Devices Market is valued at 2 Billion USD in 2026.

Dexcom, Medtronic, Novo Nordisk A/S, F. Hoffmann-La Roche AG, Abbott Diabetes Care are the major companies operating in Canada Diabetes Care Devices Market.

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!